Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesShimon Slavin, Reuven Or, Arnon Nagler et al.|Blood|1998Cited by 1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesShimon Slavin, Reuven Or, Arnon Nagler et al.|Blood|1998Cited by 1.8k
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II StudyAnas Younes, Andreas Engert, Christophe Le Corre et al.|Journal of Clinical Oncology|2012Cited by 261
Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA LevelsLeo Kretzner, Mark Kirschbaum|Cancer Research|2011Cited by 99
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Constantine S. Tam, Andrew W. Roberts, Stephen Opat et al.|Blood|2016Cited by 37